Articles On Somnomed (ASX:SOM)

Sleep apnoea treatment company SomnoMed (ASX: SOM) was caught napping in 2018 when an ambitious US direct-to-consumer model failed to deliver results, sending shares plunging and triggering a retreat and rethink. Known as Renew Sleep Solu...

Sleep apnoea — or sleep suffocation as some have taken to calling it — is big business on the ASX, spanning billion-dollar ResMed (ASX:RMD) to a group of small caps. Oventus (ASX:OVN), one of those small caps, is the latest this month to ad...

The venerable sleep disorders house is starting to sound like a car maker that has exhausted the possible names for its variant models and is now relying on letters, dashes, errant capital letters and numbers. A case in point is ResMed’s (A...

The SomnoMed Limited (ASX: SOM) share price has closed the trading day at a 52-week-high, after surging nearly 6% in today’s trading session and closing at $3.23.  The company’s share price has made a spectacular recovery in the last 12 mo...

Quarterly reports for biotechs usually only tell investors how much cash they have left — and how much time they have until the next cap raise. But December quarterlies from late Friday and today include several companies that are making mo...

Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IHL-42X in pill form. Impression intends t...

Australian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral mucosa. The company uses its exclusive OroMist® techno...

As the head of a company selling mouthguard-like oral devices to combat obstructive sleep apnoea (OSA), Neil Verdal-Austin surprises us by praising the effectiveness of the standard-of-care rival pumps and masks sold by industry leaders Res...

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform t...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

In this week’s recap of substantial holders, Australian Super became an substantial holder in Gage Roads Brewing (ASX: GRB), a prominent Sydney property magnate bought 16 per cent of Collaborate Corporation, and we look at a number of purch...

In this article, we would discuss three healthcare stocks from ASX. On 23 July 2019, these companies have released significant updates pertaining to their respective business. The Australian benchmark index was trading at 6,780.6, up by 55....

The Somnomed Limited (ASX: SOM) share price opened 6.7% higher at $1.60 today after the sleep treatment medical device business reported an operating cash profit of $798,000 on revenue of $17.95 million for the quarter ending June 30, 2019...

Health and medical industry of Australia focuses on the world’s leading technology, advanced research, development and innovation. Over the years, the industry has registered strong growth in terms of both size and reputation. Let us discus...

Investors might be taking a closer at Somnomed Limited (ASX: SOM), a healthcare business. Somnomed was founded in Sydney in 2004 and it provides diagnostic and treatment solutions for sleep-related breathing disorders including obstructive...

In morning trade the Volpara Health Technologies Ltd (ASX: VHT) share price has charged higher following the announcement of a new sales agreement. At the time of writing the medical technology company’s shares are up 4% to $3.69. What did...